Due to the extension of the deadline for submission, the notification of acceptance is delayed to the first week of April.
Instructions to authors
Carefully read the guidelines before submitting your abstract, find the guidelines here.
Upon submission, a confirmation email will be sent to the submitter’s email address. If you do not receive the confirmation e-mail, please do not submit the abstract again. Instead, please contact the Scientific Secretariat firstname.lastname@example.org for advice.
Declaration of conflict of interest
EAACI is committed to ensuring the integrity of scientific, educational, and research programmes. Abstract submission requires disclosure of any financial or other interest that might be construed as resulting in an actual, potential, or apparent conflict. The submitter is responsible for obtaining disclosure information from all co-authors, to be entered in the author section of the submission page.
When entering the abstract submission system for the first time, you will be asked to create a MyEAACI account (if you don’t have one already). Through your MyEAACI account you will be able to access your personal page to submit one or several abstracts. You can edit your abstracts until the submission deadline on Monday 16 January 2023, 23:59 CET.
Abstract language and length
Abstracts and presentations must be written in English. The maximum length allowed for an abstract is 2500 characters (approximately 350 words) including blank spaces. The abstract title, the author(s) or names of institutions are not included in the count of 2500 characters.
Consent for publication of individual patient data – applies to abstracts with identifiable patient
For the publication of an abstract that contains identifiable information about patients, it is necessary that patients have given consent for the research to be published. For all abstracts that include identifiable patient details (e.g. gender, age, illness, location) or images, written informed consent for the publication of these must be obtained from the patient (or their parent or legal guardian).
It is the author’s responsibility to obtain written informed consent for publication of clinical details and/or clinical images from the patient/parent/guardian/relative of the patient. A respective statement needs to be included in the abstract text.
Duplication of publications
Unpublished abstracts that have been presented at a different scientific meeting within a 12 months period prior to EAACI Hybrid Congress 2023, provided they contain updated/additional data, can be submitted and will be considered for presentation. Abstracts submitted for publication or to a scientific meeting, but are pending acceptance, can be submitted without restrictions. However, once the abstract has been accepted by EAACI it is automatically subject to the EAACI embargo policy.
Notification of acceptance:
Notifications of acceptance of the abstracts will be sent to the presenting author of the abstract by end of March 2023.
Registration and publication of abstracts:
The presenting author of an abstract must register for the onsite congress. Until 18 April 2023 the presenting author is offered a special extended “early fee”.
Accepted abstracts will be published in the online programme, EAACI website and EAACI content platform during the Congress. Publication of the abstracts as a supplement in the Allergy Journal will be done after the congress. Please note that your abstract will only be published in the Allergy journal if the abstract is accepted, uploaded/presented, and the presenting author is registered using the same email address used for abstract submission. In order to have your abstract published on the website you need to be registered for the congress by 18 April 2023. Kindly note that all abstracts selected for E-TPS Display Only will NOT be published on the EAACI content platform nor in the Allergy Journal.